65,437 trials
Primary Biliary Cholangitis
Primary: Percentage of Participants With At Least a 20% Reduction in Alkaline Phosphatase (ALP) or Normalization of ALP at Week 12 Compared to Baseline — 45.2; 46.4; 11.1…
Osteoarthritis, Knee
Primary: Pain; Visual Analog Scale (VAS) — 4; 4 cm
Exercise Therapy · Metabolic Syndrome X · Cardiorespiratory Fitness
Primary: Systolic Blood Pressure — 126; 134; 124; 133 mmHg — p=0.040
End-Stage Renal Disease · Meals · Hemodialysis
Primary: Hypotensive Event Frequency — 18; 13 events
Neuromuscular Blockade
Primary: Application of Objective Neuromuscular Monitoring (Acceleromyography) in Cases Receiving a Depolarizing Neuromuscular Blocking Agent (NMBA) (Succinylcholine) (Yes/no)…
Post Thrombotic Syndrome · Deep Vein Thrombosis
Primary: Feasibility as Measured by Number of Participants Who Meet Study Eligibility Criteria at Baseline — 40 Participants
Nursing Students Education on Neonatal Resuscitation
Primary: Knowledge Questionnaire — 5.90; 5.87; 9.97; 13.33 score on a scale
Endothelial Dysfunction
Primary: Area Under the Curve (AUC0-12hrs) of Plasma BH4 Concentration — 633; 993 nM*hr — p=<0.001
Psoriasis
Primary: Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 During the Placebo-Controlled Phase — 4.1; 21.6 Percentage of…
Body Fat Disorder
Primary: Proportion of Accurately Identified Pre-Treatment Photos by a Panel of Blinded Independent Reviewers — 11 photos
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Major Pathologic Response (MPR) — 20.3 percentage of participants — p=<.0001
Osteoarthritis
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF)…
Stable Coronary Artery Disease
Primary: Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation — 102; 103; 18 Count of participants (i.e., responders)…
Triple Negative Breast Cancer
Primary: Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants — 5.49; 7.16 Months…
MRI Scans · Magnetic Resonance Imaging · Pacemaker
Primary: Number of Participants With Burning or Pulling Sensations in Chest/Device Pocket During MRI — 2 Participants